Aridis Pharmaceuticals, Inc. (ARDS) stock rallied over 1.82% intraday to trade at $1.12 a share on NASDAQ. The stock opened with a loss of -2.61% at $1.07 and touched an intraday high of $1.14, rising 1.82% against the last close of $1.1. The stock went to a low of $1.06 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue1.53 Million
5Y Sales Change-7.50%
Fiscal Year Ends2021-12-30
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) stock price is $1.12 as of the last check on Wednesday, July 6. During the trading session, ARDS stock reached the peak price of $1.14 while $1.06 was the lowest point it dropped to.
The NASDAQ listed ARDS is part of Biotechnology industry that operates in the broader Health Care sector. Aridis Pharmaceuticals, Inc. , a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections.
Dr. Vu L. Truong
Founder, CEO & Director
Dr. Vu L. Truong Ph.D.
Founder, CEO, Chief Scientific Officer & Director
Mr. Fred Kurland J.D., M.B.A.
Chief Financial Officer
Dr. Hasan Jafri M.D.
Chief Medical Officer
ARDS stock traded closed the last session at $1.12, which is $0.02 or 1.82% lower than its previous close of $1.1. ARDS's current trading price is 27.27% lower than its 52-week high of $7.69 where as its distance from 52-week low of 0.88% is -85.44%.
Number of ARDS employees currently stands at -. ARDS operates from 983 University Avenue, Building B, Los Gatos, CA 95032, United States.
Official Webiste of $ARDS is: https://www.aridispharma.com
ARDS stock volume for the day was 25,341 shares while in the previous session number of ARDS shares traded was 25,246 . The average number of ARDS shares traded daily for last 3 months was 58.66 Thousands.
The percentage change in ARDS stock occurred in the recent session was 1.82% while the dollar amount for the price change in ARDS stock was $0.02.
In the recent session, the day high for ARDS stock was $1.14 while the low for ARDS stock touched on the day was $1.06.
The market value of ARDS currently stands at 19.86 Million with its latest stock price at $1.12 and 17.7 Million of its shares outstanding.